Loading
OSE Immunotherapeutics Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 08 Dec 2021.
OSE Immunotherapeutics: what insiders have been doing
OSE Immunotherapeutics, founded in 2016, is a Healthcare & Pharma company based in Paris, France. Its directors and officers file their transactions with AMF. The last twelve months, up to 18 October 2026, brought 1 filing signed by 1 insider.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
For context, the typical company on the same exchange (median of 316 companies) published 6 filings over the same period, against 1 filing here. Our records for OSE Immunotherapeutics go back to 2021, with 1 purchase and 4 sales on the open market in total.
Over the last twelve months, not one insider purchase of OSE Immunotherapeutics stock was filed.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by AMF and describes the past, not future prices; it is not investment advice.
Key facts
Headquarters: Paris, France · Founded: 2016
Source: Wikidata (CC0).
Insider Decl.
11
Thresholds
n/a
Buy Volume
€202,719
1 ops. · all time
Sell Volume
€760,548
4 ops. · all time
Who traded when
BuySaleAnne-Laure Autret-Cornet1 sale
Maryonne Hiance1 sale
Since the insiders bought
- -29.6%Entry €9.86 · Close at T+365 €6.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate OSE Immunotherapeutics Strong Buy (bullish), based on 4 analysts. Average price target: €12.70.
Financial data
as of FY 2025FY ended December 2025 · cache
€2.14
Analyst consensus
4 analystsStrong buy
€8.20Target €12.70(+492%)€21.00
Income statement
Revenue€2.6M
EBITDA-€31.3M-1197% margin
Net income-€37.7M-1439.1% margin
Valuation
PER (forward)-1.9x
P/Book1.7x
Beta0.83
Balance sheet & cash
Market cap€53.0M
Total debt€35.4M
Free Cash Flow-€34.1M
Debt / Equity72%
Profitability & ownership
ROE-82.3%
ROA-23.1%
% insiders25.4%
% institutions2.7%
Last declaration on 5 June 2026
Declarations11 total
100,000 shares0ActionEuronext ParisISIN FR00121271732026DD1118892
100,000 shares@ €3.57100.0% of flowBPCEEuronext ParisISIN FR00121271732025DD1059118
90,000 shares@ €0.396730.4% of flowBSPCEEuronext ParisISIN FR00121271732025DD1058931
30,000 shares@ €10.009346.2% of flowActionEuronext ParisISIN FR00121271732024DD1005129
10,000 shares@ €9.9878100.0% of flowActionEuronext ParisISIN FR00121271732024DD1004901
10,000 shares@ €3.575.5% of flowActionEuronext ParisISIN FR00121271732024DD982158
10,000 shares@ €3.5830.5% of flowOption d'achatEuronext ParisISIN FR00121271732024DD971951
10,000 shares@ €3.5715.0% of flowActionEuronext ParisISIN FR00121271732024DD971661
6,369 shares@ €7.203539.1% of flowActionEuronext ParisISIN FR00121271732024DD971114
40,000 shares@ €7.862848.3% of flowActionEuronext ParisISIN FR00121271732024DD970613
18,500 shares@ €10.957885.0% of flowActionEuronext ParisISIN FR00121271732021DD759546
Canonical exit: 6 Sept 2021 (T+90)
11 of 11 declarations
About OSE Immunotherapeutics
OSE Immunotherapeutics is a French biotechnology company focused on the discovery, development and commercialization of innovative immunotherapy-based treatments. Listed on Euronext Paris under the ticker OSE and ISIN FR0012127173, the company is headquartered in Nantes and Paris and relies on an international network of scientific, clinical and industrial experts. Its business model combines proprietary clinical-stage programs, strategic alliances with major pharmaceutical companies and academic collaborations, aiming to generate value while managing the inherent risk of drug development.
The company’s history dates back to the creation of OSE Pharma in 2012 by Dominique Costantini and Émile Loria. OSE Pharma was listed on Euronext Paris in 2015 with Tedopi®, a therapeutic cancer vaccine, as its lead asset. The company then expanded significantly through the merger of OSE Pharma and Effimune, completed on May 31, 2016, which formed OSE Immunotherapeutics and broadened its focus toward both immuno-oncology and immuno-inflammation.
Read moreShow less
OSE’s portfolio is structured around two main therapeutic areas. In immuno-oncology, Tedopi® remains the most advanced asset: it is an off-the-shelf, neoepitope-based immunotherapy mainly developed for non-small cell lung cancer. In 2024, the company launched ARTEMIA, its pivotal international Phase 3 study in this indication. In immuno-inflammation, Lusvertikimab (OSE-127) is a first-in-class monoclonal antibody targeting IL-7R, being developed primarily in ulcerative colitis and other chronic inflammatory diseases. The pipeline is complemented by partnered and preclinical assets, including programs with AbbVie, Boehringer Ingelheim and Memorial Sloan Kettering.
OSE Immunotherapeutics’ competitive position is built on a focused strategy centered on next-generation immune mechanisms, a high R&D intensity and exposure to areas of substantial unmet medical need. The company differentiates itself through a translational research platform and a strong network of scientific partnerships. Its 2024 industrial agreements materially strengthened the balance sheet and improved financing visibility, with recent company disclosures indicating cash visibility through 2027.
Beyond France, OSE maintains an international footprint through multicenter clinical trials, global partnerships and engagement with leading pharmaceutical players. Notable facts include public funding support from France 2030 for Tedopi®, the licensing agreement with AbbVie for ABBV-230 and the expanded collaboration with Boehringer Ingelheim across several immuno-oncology assets. Overall, OSE Immunotherapeutics stands out as a specialty biotech stock centered on clinical innovation and long-term value creation.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
